Clinical And MicroRNA Study Of Huoxue Huatan Anshen Recipe On Patients With Coronary Heart Disease And Angina Pectoris With Phlegm And Blood Stasis Syndrome

The part Ⅰ:The clinical research of Huoxuehuatan’anshen prescription for patients with coronary heart disease (CHD) angina pectoris and phlegm and blood stasis syndrome.Objective:To evaluate the efficacy and safety of Huoxuehuatan’anshen prescription for patients with angina pectoris in CHD and phlegm and blood stasis syndrome.Methods:This research collected 73 patients in cardiovascular department of Guang’anmen Hospital from January 2015 to September 2015. Outpatients and inpatients were acceptable. There were 60 patients ultimately after abandoning the number of loss. Among them, the treatment group included 30 patients and the control group had 30 patients. On the basis of conventional western medicine treatment, the treatment group was given Huoxuehuatan’an shen prescription, and the control group was given placebo, twice a day, four weeks for a treatment course. Filling in Case Report Form (CRF) in pre-treatment and post-treatment, and observing the basic information, the safety index and clinical effects of patients after a treatment course.Results:1 The treatment group was superior to the control group in angina pectoris symptom scores, P=0.044;2 The treatment group was superior to the control group in syndrome evaluation, P=0.03;3 The treatment group was superior to the control group in therapeutic effect of syndrome, P=0.012;4 The treatment group didn’t have obvious adverse reactions through examing blood, urine, stool routine, liver and kidney function, blood coagulation, blood lipid and so on.Conclusion:Huoxuehuatan’anshen prescription had a good therapeutic effect and security in treating angina pectoris in CHD and phlegm and blood stasis syndrome.The partⅡ:The microRNA study of Huoxuehuatan’anshen prescription for patients with angina pectoris in CHD and phlegm and blood stasis syndrome.Objective:1 The difference of microRNA between patients in CHD and healthy people by miRNA chip.2 The difference of microRNA between the treatment group and the control group.Methods:1 There are three groups including the treatment group, the control group and healthy people. Each group owns 3 cases. Drawing blood, separating peripheral blood mononuclear cell, extracting total RNA and testing by microRNA chip.2 Choosing differential expression of microRNA accordding to log2(Ratio) and P-value. Using miRwalk software predicts target genes and DAVID 6.7 conducts KEGG pathway.3 To determine the key microRNA and their signaling pathways.Results:1 The microRNAs changed between patients in CHD and healthy people. These microRNAs had a high expression, such as miR-1207-5p, miR-132, miR-320d, miR-765 et al. The relative cell signaling pathway was mainly TGF-β cell signaling pathway. These microRNAs had a low expression, such as miR-1181, miR-1225-3p, miR-1233, miR-1236, miR-1248, miR-668, miR-1281, miR-1538, miR-181d, miR-342-3p, miR-483-3p, miR-494, miR-491-3p, miR-98 miR-532-3p et al. The relative cell signaling pathways were TGF-β cell signaling pathway, Apoptosis, MAPK signaling pathway, p53 signaling pathway, Wnt signaling pathway et al.2 The microRNAs changed between pre-treatment and post-treatment of the treatment group. These microRNAs had a high expression, such as miR-107, miR-146b-5p, miR-199a-5p, miR-661 et al. The relative cell signaling pathway was mainly MAPK cell signaling pathway. These microRNAs had a low expression, such as miR-1321. The relative cell signaling pathway was Melanogenesis.3 The microRNAs didn’t change between pre-treatment and post-treatment of the conrol group.4 The microRNAs have changed between the treatment group and the conrol group after the treatment course. These microRNAs had a high expression, such as miR-1275 et al. The relative cell signaling pathways was Calcium signaling pathway.Conclution:1 There were differences of microRNAs between patients in CHD and healthy people.2 There were differences of microRNAs between pre-treatment and post-treatment of the treatment group.3 There weren’t differences of microRNAs between pre-treatment and post-treatment of the conrol group.4 There were differences of microRNAs between the treatment group and the conrol group.